Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML.

Clin Cancer Res. 2018 Sep 21. doi: 10.1158/1078-0432.CCR-18-1763. [Epub ahead of print]

PMID:
30242022
2.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

PMID:
30232083
3.

An Epithelioid Smooth Muscle Neoplasm Mimicking a Signet Ring Cell Carcinoma in the Ovary.

Xing D, Berrebi AA, Liu C, Richmond A, Vang R, Ronnett BM.

Int J Gynecol Pathol. 2018 May 10. doi: 10.1097/PGP.0000000000000520. [Epub ahead of print]

PMID:
29750703
4.

Clinicopathologic Features and Genetic Alterations of a Primary Osteosarcoma of the Uterine Corpus.

Zheng G, Richmond A, Liu C, Berrebi A, Pallavajjala A, Haley L, Stone RL, McCarthy E, Vang R, Xing D.

Int J Gynecol Pathol. 2018 Apr 6. doi: 10.1097/PGP.0000000000000511. [Epub ahead of print]

PMID:
29629977
5.

Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.

Xing D, Zheng G, Schoolmeester JK, Li Z, Pallavajjala A, Haley L, Conner MG, Vang R, Hung CF, Wu TC, Ronnett BM.

Am J Surg Pathol. 2018 Jun;42(6):750-760. doi: 10.1097/PAS.0000000000001042.

PMID:
29505425
6.

Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.

Xing D, Banet N, Sharma R, Vang R, Ronnett BM, Illei PB.

Hum Pathol. 2018 Feb;72:160-166. doi: 10.1016/j.humpath.2017.10.036. Epub 2017 Dec 11.

PMID:
29241740
7.

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Morrow MP, Kraynyak KA, Sylvester AJ, Dallas M, Knoblock D, Boyer JD, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY, Kim JJ, Plotkin S, Weiner DB, Trimble CL, Bagarazzi ML.

Clin Cancer Res. 2018 Jan 15;24(2):276-294. doi: 10.1158/1078-0432.CCR-17-2335. Epub 2017 Oct 30.

PMID:
29084917
8.

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.

Xing D, Suryo Rahmanto Y, Zeppernick F, Hannibal CG, Kjaer SK, Vang R, Shih IM, Wang TL.

Hum Pathol. 2017 Oct;68:87-91. doi: 10.1016/j.humpath.2017.08.021. Epub 2017 Sep 2.

9.

Performance test and verification of an off-the-shelf automated avian radar tracking system.

May R, Steinheim Y, Kvaløy P, Vang R, Hanssen F.

Ecol Evol. 2017 Jun 22;7(15):5930-5938. doi: 10.1002/ece3.3162. eCollection 2017 Aug.

10.

Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Vang R, Hannibal CG, Junge J, Frederiksen K, Kjaer SK, Kurman RJ.

Am J Surg Pathol. 2017 Jun;41(6):725-737. doi: 10.1097/PAS.0000000000000824.

11.

Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas.

Sangoi AR, Kshirsagar M, Roma AA, Horvai AE, Chivukula M, Ellenson LH, Fadare O, Folkins AK, Garg K, Hanley K, Longacre TA, Haas J, McCluggage WG, McKenney JK, Nucci MR, Oliva E, Park KJ, Parkash V, Quick CM, Rabban JT, Rutgers JKL, Soslow R, Vang R, Yemelyanova A, Zaloudek C, Beck AH.

Int J Gynecol Pathol. 2017 Jul;36(4):386-392. doi: 10.1097/PGP.0000000000000329.

PMID:
28221217
12.

Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.

Rasmussen ELK, Hannibal CG, Dehlendorff C, Baandrup L, Junge J, Vang R, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2017 Mar;144(3):571-576. doi: 10.1016/j.ygyno.2017.01.002. Epub 2017 Jan 17.

PMID:
28108026
13.

A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2017 Jan;144(1):174-180. doi: 10.1016/j.ygyno.2016.11.007. Epub 2016 Nov 9.

14.

Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system.

Voltaggio L, Cimino-Mathews A, Bishop JA, Argani P, Cuda JD, Epstein JI, Hruban RH, Netto GJ, Stoler MH, Taube JM, Vang R, Westra WH, Montgomery EA.

CA Cancer J Clin. 2016 Sep;66(5):408-36. doi: 10.3322/caac.21350. Epub 2016 Jun 6. Review.

15.

Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases.

Seidman JD, Krishnan J, Yemelyanova A, Vang R.

Int J Gynecol Pathol. 2016 Sep;35(5):423-9. doi: 10.1097/PGP.0000000000000267.

PMID:
26630221
16.

Invasive Complete Hydatidiform Moles: Analysis of a Case Series With Genotyping.

Bynum J, Murphy KM, DeScipio C, Beierl K, Adams E, Anderson D, Vang R, Ronnett BM.

Int J Gynecol Pathol. 2016 Mar;35(2):134-41. doi: 10.1097/PGP.0000000000000232.

PMID:
26535984
17.

Carcinoma of the Uterine Cervix Involving the Genitourinary Tract: A Potential Diagnostic Dilemma.

Schwartz LE, Khani F, Bishop JA, Vang R, Epstein JI.

Am J Surg Pathol. 2016 Jan;40(1):27-35. doi: 10.1097/PAS.0000000000000524.

PMID:
26426382
18.

Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins.

Wang Y, Schwartz LE, Anderson D, Lin MT, Haley L, Wu RC, Vang R, Shih IeM, Kurman RJ.

Oncotarget. 2015 Sep 8;6(26):22949-58.

19.

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.

Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.

20.

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L; International Collaboration on Cancer Reporting.

Mod Pathol. 2015 Aug;28(8):1101-22. doi: 10.1038/modpathol.2015.77. Epub 2015 Jun 19. Review.

21.

Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification.

Seidman JD, Vang R, Ronnett BM, Yemelyanova A, Cosin JA.

Gynecol Oncol. 2015 Feb;136(2):336-40. doi: 10.1016/j.ygyno.2014.12.018. Epub 2014 Dec 17.

PMID:
25528497
22.

Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.

Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM.

Am J Surg Pathol. 2015 Apr;39(4):442-53. doi: 10.1097/PAS.0000000000000352.

PMID:
25517955
23.

GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Banet N, Gown AM, Shih IeM, Kay Li Q, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasseri-Nik N, Wu LS, Netto GJ, Ronnett BM, Vang R.

Am J Surg Pathol. 2015 Jan;39(1):101-8. doi: 10.1097/PAS.0000000000000315.

24.

BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IeM.

Am J Surg Pathol. 2014 Dec;38(12):1603-11. doi: 10.1097/PAS.0000000000000313. Erratum in: Am J Surg Pathol. 2015 Jul;39(7):1014.

25.

PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.

Yemelyanova A, Gown AM, Wu LS, Holmes BJ, Ronnett BM, Vang R.

Int J Gynecol Pathol. 2014 Sep;33(5):492-9. doi: 10.1097/PGP.0b013e3182a54afa.

PMID:
25083965
26.

A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies.

Cimino-Mathews A, Sharma R, Illei PB, Vang R, Argani P.

Am J Surg Pathol. 2014 Dec;38(12):1689-96. doi: 10.1097/PAS.0000000000000301.

27.

A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kjaerbye-Thygesen A, Andersen KK, Tabor A, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2014 Aug;134(2):267-73. doi: 10.1016/j.ygyno.2014.06.002. Epub 2014 Jun 10.

28.

A subset of nondescript axillary lymph node inclusions have the immunophenotype of endosalpingiosis.

Carney E, Cimino-Mathews A, Argani C, Kronz J, Vang R, Argani P.

Am J Surg Pathol. 2014 Dec;38(12):1612-7. doi: 10.1097/PAS.0000000000000261.

29.

PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).

Holmes BJ, Gown AM, Vang R, Ronnett BM, Yemelyanova A.

Int J Gynecol Pathol. 2014 Jul;33(4):425-31. doi: 10.1097/PGP.0b013e31829d7705.

PMID:
24901404
30.

Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.

Cox R, Vang R, Epstein JI.

Am J Surg Pathol. 2014 May;38(5):713-8. doi: 10.1097/PAS.0000000000000152.

PMID:
24441657
31.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.

J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.

32.

Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.

Nik NN, Vang R, Shih IeM, Kurman RJ.

Annu Rev Pathol. 2014;9:27-45. doi: 10.1146/annurev-pathol-020712-163949. Epub 2013 Aug 5. Review.

PMID:
23937438
33.

A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.

Cimino-Mathews A, Hicks JL, Sharma R, Vang R, Illei PB, De Marzo A, Emens LA, Argani P.

Hum Pathol. 2013 Nov;44(11):2494-500. doi: 10.1016/j.humpath.2013.06.009. Epub 2013 Jul 31.

34.

Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.

Bagby C, Ronnett BM, Yemelyanova A, Maleki Z, Kuhn E, Vang R.

Int J Gynecol Pathol. 2013 Sep;32(5):433-43. doi: 10.1097/PGP.0b013e31826a6446.

PMID:
23896706
35.

Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping.

Banet N, DeScipio C, Murphy KM, Beierl K, Adams E, Vang R, Ronnett BM.

Mod Pathol. 2014 Feb;27(2):238-54. doi: 10.1038/modpathol.2013.143. Epub 2013 Jul 26.

36.

Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively.

Vandenbussche CJ, Khouri N, Sbaity E, Tsangaris TN, Vang R, Tatsas A, Cimino-Mathews A, Argani P.

Am J Surg Pathol. 2013 Jun;37(6):913-23. doi: 10.1097/PAS.0b013e31828ba25c.

37.

GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.

Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, Fetting JH, Park BH, Argani P.

Hum Pathol. 2013 Jul;44(7):1341-9. doi: 10.1016/j.humpath.2012.11.003. Epub 2013 Jan 31.

38.

Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease.

Lewis GH, DeScipio C, Murphy KM, Haley L, Beierl K, Mosier S, Tandy S, Cohen DS, Lytwyn A, Elit L, Vang R, Ronnett BM.

Int J Gynecol Pathol. 2013 Mar;32(2):199-214. doi: 10.1097/PGP.0b013e3182630d8c.

PMID:
23370656
39.

Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.

Vang R, Shih IeM, Kurman RJ.

Histopathology. 2013 Jan;62(1):44-58. doi: 10.1111/his.12046. Review.

PMID:
23240669
40.
41.

Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists.

Gupta M, Vang R, Yemelyanova AV, Kurman RJ, Li FR, Maambo EC, Murphy KM, DeScipio C, Thompson CB, Ronnett BM.

Am J Surg Pathol. 2012 Dec;36(12):1747-60. doi: 10.1097/PAS.0b013e31825ea736.

42.

The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features.

Fadare O, Parkash V, Dupont WD, Acs G, Atkins KA, Irving JA, Pirog EC, Quade BJ, Quddus MR, Rabban JT 3rd, Vang R, Hecht JL.

Am J Surg Pathol. 2012 Aug;36(8):1107-18. doi: 10.1097/PAS.0b013e31825dd4b3. Erratum in: Am J Surg Pathol. 2013 Mar;37(3):458.

PMID:
22790851
43.

Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.

Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM.

Int J Gynecol Pathol. 2012 Jul;31(4):297-303. doi: 10.1097/PGP.0b013e31823f8482.

44.

Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.

Vang R, Visvanathan K, Gross A, Maambo E, Gupta M, Kuhn E, Li RF, Ronnett BM, Seidman JD, Yemelyanova A, Shih IeM, Shaw PA, Soslow RA, Kurman RJ.

Int J Gynecol Pathol. 2012 May;31(3):243-53. doi: 10.1097/PGP.0b013e31823b8831.

45.

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2012 Jun;125(3):655-60. doi: 10.1016/j.ygyno.2012.02.028. Epub 2012 Feb 24.

46.

Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis.

Vang R, Gupta M, Wu LS, Yemelyanova AV, Kurman RJ, Murphy KM, Descipio C, Ronnett BM.

Am J Surg Pathol. 2012 Mar;36(3):443-53. doi: 10.1097/PAS.0b013e31823b13fe.

47.

MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.

Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P.

Mod Pathol. 2012 Mar;25(3):378-87. doi: 10.1038/modpathol.2011.171. Epub 2011 Nov 4.

48.

Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.

Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih IeM.

Am J Surg Pathol. 2011 Nov;35(11):1605-14. doi: 10.1097/PAS.0b013e318229449f.

49.

TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.

Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih IeM.

J Pathol. 2012 Feb;226(3):421-6. doi: 10.1002/path.3023. Epub 2011 Dec 23.

50.

Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, Shih IeM, Kurman RJ.

Am J Surg Pathol. 2011 Dec;35(12):1766-75. doi: 10.1097/PAS.0b013e31822f58bc.

Supplemental Content

Support Center